EU fidaxomicin approval another feather in Optimer's 2011 cap
This article was originally published in Scrip
Executive Summary
In the second major regulatory clearance for the product this year, the European Commission has granted a marketing authorisation to Optimer Pharmaceuticals/Astellas' first-in-class antibiotic for Clostridium difficile infections Dificlir (fidaxomicin), clearing the way for a new treatment option for what can be a fatal disorder.